Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This was a multiple dose, dose escalation study designed to determine the safety,
tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants
with transthyretin (TTR) mediated amyloidosis (ATTR).